Salvage use of erlotinib in advanced non-small cell lung cancer with acquired resistance to gefitinib: Is a clinical benefit still achievable?

Chul Cho Byoung, Hang Kim Joo

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Salvage use of erlotinib in advanced non-small cell lung cancer with acquired resistance to gefitinib: Is a clinical benefit still achievable?'. Together they form a unique fingerprint.